Advertisement

St. Baldrick’s commits $8 million to SU2C Pediatric Cancer Dream Team

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The work of the Stand Up to Cancer-St. Baldrick’s Foundation Pediatric Cancer Dream Team, launched in 2013 to help develop new immunotherapy approaches to high-risk childhood cancers, will continue with a commitment of $8 million from the St. Baldrick’s Foundation, the world’s largest private funder of childhood cancer research grants. To further the impact of this gift, the eight institutions that make up the consortium have committed matching dollars to a total of $16 million.

Continuing as co-leaders of the newly charged St. Baldrick’s-Stand Up to Cancer Pediatric Cancer Dream Team are John Maris, pediatric oncologist and holder of the Giulio D’Angio Chair in Neuroblastoma Research at Children’s Hospital of Philadelphia, and Crystal Mackall, professor of pediatrics (hematology and oncology) at Stanford University and associate director of the Stanford Cancer Institute.

Advertisement

St. Baldrick’s and Stand Up to Cancer initially provided the Dream Team, consisting of more than 150 researchers at eight institutions, with $14.5 million over a four-year term beginning in 2013. The Dream Team worked to improve and expand immunotherapy in childhood cancers.

Advertisement
Advertisement

YOU MAY BE INTERESTED IN

The day before health economist Jay Bhattacharya stepped into his new role as NIH director, he sent a document to his employees outlining his top five priorities for the department, which included “reproducibility” and “transparency,” two themes he discussed at his confirmation hearings (The Cancer Letter, March 7, 2025).
Advertisement
Advertisement